Aller au contenu principal
Accès ouvert déclaré 2022 article

The Safety and Effectiveness of a Polysaccharide Extracted from Rosa Canina in Patients with NAFLD: A Randomized Trial

1Citations signalées — pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Objective: Non-alcoholic fatty liver (NAFL) is a common pathology of hepatocytes due to the accumulation of fat which is predominantly implicated in obesity. Due to the multifaceted characterization of fatty liver and no effective treatment, this study was aimed to assess the protective effect of a polysaccharide in NAFL patients. Materials and methods: Polysaccharide fraction was isolated from Rosa canina and administered to 33 NAFL patients for 90 days. Demographic information, liver ultrasonography, and the activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes were studied. Data were analyzed with the use of SPSS version 21 (SPSS, Inc.) All data were shown as means ± SDs and p < 0.05 was considered as significant. Results: After 90-day prescription, the weight loss, reduced activity of ALT and AST as well as changing the echogenicity of the liver from grades of 3, 2, and 1 to 2, 1 and normal, respectively, were observed in patients compared to the baseline (p ≤ 0.05). In addition, there were no visible side effects in patients during drug consumption. Conclusions: The data indicated that polysaccharide fraction with no obvious side effects is significantly able to protect the liver from steatosis in patients with NAFL disease. However, further information is required to better conclude on the effectiveness of the isolated polysaccharide as a promising fatty liver drug.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The Safety and Effectiveness of a Polysaccharide Extracted from Rosa Canina in Patients with NAFLD: A Randomized Trial
Date Crossref
31/08/2022
Éditeur
VM Media SP. zo.o VM Group SK
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseDiet and metabolism studies

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.